New Raltegravir Potassium Merck Agreement Proves to be a Major Improvement Over the Status Quo


Raltegravir potassium 871038-72-1
Anti-Retroviral / Anti-HIV, Drug Research & Development API, Patent Expiration 2023

Raltegravir potassium is a human immunodeficiency virus integrase strand transfer inhibitor. The drug is soluble in water and slightly soluble in ethanol and methanol as well. The pharmaceutically acceptable salt has been approved for the treatment of HIV-1.

The multinational pharmaceutical, Merck has signed an agreement with MPP (Medicines Patent Pool) to license its intellectual property relating to the formulation of Raltegravir, the company’s integrase HIV drug. According to reports, the new agreement should clear the way for cheaper formulations which can be developed for some middle income countries. The license is royalty free, and because of the terms of Agreement, drug manufacturers from around the world can now develop the drug formulations of Raltegravir along with other novel combinations.

By following in the footsteps of some of the biggest names in the pharmaceutical industry, Merck has now actually made it possible for manufacturers to sell pediatric versions of their medication, but only in licensed countries and under the agreed terms. This deal between the company and MPP is the first of its kind and has made it easier for people who are living with HIV in developing countries to get easy access to a cheap medication that can very well save their lives.

According to reports, the whole idea behind the deal is to lower the price of the drug, by facilitating in the drug’s development, especially for third world countries, which now have a better chance at surviving HIV. The Agreement covers 92 countries and according to the MPP, 98.1% of children with HIV are living in those developing countries.

As suppliers/distributors, LGM Pharma is able to assist you in acquiring Raltegravir potassium CAS# 871038-72-1 in order to carry out clinical trials specifying new formulation, dosages and delivery systems. Rest assured, we will provide you with premium quality API products along with the continuous support of our team throughout the entire R&D process.

General Disease Facts

HIV or human immunodeficiency virus is a virus that is responsible for the AIDS pandemic. The virus comes in two strains, HIV-1 and HIV-2. The main reason for this is that each time the HIV is able to replicate itself, small changes occur which lead to the various forms of HIV. Out of the two, the most predominant virus is HIV-1, and it’s the one that is generally talked about when discussing HIV or AIDS. This strain can also be classified into four groups, the most common one of the group being ‘M’ or ‘Major’.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13 (1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share: